methylphenidate has been researched along with Neurofibromatosis 1 in 7 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Neurofibromatosis 1: An autosomal dominant inherited disorder (with a high frequency of spontaneous mutations) that features developmental changes in the nervous system, muscles, bones, and skin, most notably in tissue derived from the embryonic NEURAL CREST. Multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. Peripheral and central nervous system neoplasms occur frequently, especially OPTIC NERVE GLIOMA and NEUROFIBROSARCOMA. NF1 is caused by mutations which inactivate the NF1 gene (GENES, NEUROFIBROMATOSIS 1) on chromosome 17q. The incidence of learning disabilities is also elevated in this condition. (From Adams et al., Principles of Neurology, 6th ed, pp1014-18) There is overlap of clinical features with NOONAN SYNDROME in a syndrome called neurofibromatosis-Noonan syndrome. Both the PTPN11 and NF1 gene products are involved in the SIGNAL TRANSDUCTION pathway of Ras (RAS PROTEINS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with methylphenidate (MPD) has improved learning disabilities in ADHD by acting on neurotransmitters." | 2.79 | The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial. ( Bréant, V; Combemale, P; Coutinho, V; des Portes, V; Gérard, D; Ginhoux, T; Gueyffier, F; Herbillon, V; Kassaï, B; Kemlin, I; Lion-François, L; Mercier, C; Peyric, E; Pinson, S; Rodriguez, D, 2014) |
| "Forty-six of 93 children with neurofibromatosis type 1 (NF1) were found to satisfy the diagnostic criteria for attention-deficit-hyperactivity disorder (ADHD)." | 2.70 | Treatment of ADHD in neurofibromatosis type 1. ( Kluwe, L; Leark, RA; Mautner, VF; Thakker, SD, 2002) |
| "Using an Nf1 optic glioma (OPG) GEM model, we report novel defects in non-selective and selective attention without an accompanying hyperactivity phenotype." | 1.36 | Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. ( Brown, JA; Conyers, SB; Emnett, RJ; Gutmann, DH; O'Malley, KL; White, CR; Wozniak, DF; Yuede, CM, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pride, NA | 1 |
| Barton, B | 1 |
| Hutchins, P | 1 |
| Coghill, DR | 1 |
| Korgaonkar, MS | 1 |
| Hearps, SJC | 1 |
| Rouel, M | 1 |
| Malarbi, S | 1 |
| North, KN | 1 |
| Payne, JM | 1 |
| Lidzba, K | 1 |
| Granstroem, S | 1 |
| Leark, RA | 2 |
| Kraegeloh-Mann, I | 1 |
| Mautner, VF | 3 |
| Lion-François, L | 1 |
| Gueyffier, F | 1 |
| Mercier, C | 1 |
| Gérard, D | 1 |
| Herbillon, V | 1 |
| Kemlin, I | 1 |
| Rodriguez, D | 1 |
| Ginhoux, T | 1 |
| Peyric, E | 1 |
| Coutinho, V | 1 |
| Bréant, V | 1 |
| des Portes, V | 1 |
| Pinson, S | 1 |
| Combemale, P | 1 |
| Kassaï, B | 1 |
| Brown, JA | 2 |
| Emnett, RJ | 1 |
| White, CR | 1 |
| Yuede, CM | 1 |
| Conyers, SB | 1 |
| O'Malley, KL | 1 |
| Wozniak, DF | 2 |
| Gutmann, DH | 2 |
| Xu, J | 1 |
| Diggs-Andrews, KA | 1 |
| Mach, RH | 1 |
| Kluwe, L | 1 |
| Thakker, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comportemental and Neuropsychologic Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate. A Double-blind Randomised Study Methylphenidate Versus Placebo[NCT00169611] | Phase 4 | 80 participants (Anticipated) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for methylphenidate and Neurofibromatosis 1
| Article | Year |
|---|---|
Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial.
Topics: Adolescent; Central Nervous System Stimulants; Child; Child Behavior; Clinical Protocols; Cognition; | 2018 |
The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial.
Topics: Child; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up | 2014 |
Treatment of ADHD in neurofibromatosis type 1.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Behavior; Central Nervous System Stimulant | 2002 |
4 other studies available for methylphenidate and Neurofibromatosis 1
| Article | Year |
|---|---|
Pharmacotherapy of attention deficit in neurofibromatosis type 1: effects on cognition.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Child; Cognition; Dopamine Uptake I | 2014 |
Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Brain; Child; Corpus Striatum; Do | 2010 |
PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Carbon Radioisotopes; Corpus Stri | 2011 |
[Stimulant drugs in neurofibromatosis type 1 and attention deficit disorder].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2002 |